Global Paresthesia Treatment Market Trends and Insights
Rising Burden of Diabetes, Cancer, Neurological Disorders, and Aging
Diabetic neuropathy is creating sustained demand across the paresthesia treatment market. The IDF reported 589 million adults with diabetes in 2024, with a concentration among people aged 65 to 79 years, where prevalence reached 23.7%.A pooled analysis of 155 studies found diabetic peripheral neuropathy in 36% of people with diabetes globally and in 39% of cohorts in developing countries. Cancer treatment also adds a meaningful need for care because chemotherapy can cause persistent peripheral neuropathy. ASCO identifies duloxetine as the recommended medicine for established painful chemotherapy-induced peripheral neuropathy, while recognizing the limits of available treatment options. The paresthesia treatment market also benefits from aging, which increases exposure to diabetes, nerve compression, vascular insufficiency, and vitamin B12 deficiency.Shift Toward Non-Opioid and Targeted Neuropathic Pain Therapies
Clinical and regulatory priorities are moving treatment away from opioid-centered pain care. The FDA approved Vertex Pharmaceuticals’ Journavx, or suzetrigine, in January 2025 as an oral non-opioid treatment for moderate to severe acute pain. Vertex is also studying the medicine in painful peripheral neuropathic pain, which may extend its relevance beyond acute pain. ADA guidance supports care that addresses pain, sleep, and mood together in diabetic peripheral neuropathy, making multidisciplinary treatment more important. Research published in 2025 reported that opioids, including tramadol and tapentadol, are discouraged as first- or second-line treatments for diabetic neuropathic pain. This change supports the paresthesia treatment market by widening the role of medicines, rehabilitation, and targeted interventions.Limited Long-Term Efficacy, Adverse Effects, and Diagnostic Uncertainty
First-line medicines do not provide adequate pain control for every patient. A 2025 clinical review described the continuing limits of pregabalin, duloxetine, amitriptyline, and other established options for diabetic peripheral neuropathy. Sedation, dizziness, peripheral edema, weight gain, and dependence concerns can limit use of gabapentinoids, particularly among older patients with several medicines. Symptoms may result from diabetes, demyelination, chemotherapy, nerve injury, or other causes, making diagnosis and treatment selection more difficult. This uncertainty can delay care and slow uptake across the paresthesia treatment market.Other drivers and restraints analyzed in the detailed report include:
- Specialist Infrastructure and Paresthesia-Independent Neuromodulation
- Care Models for Chronic Neuropathic Symptoms
- Procedural Costs, Reimbursement Gaps, and Conventional Stimulation Tolerance
Segment Analysis
Acute paresthesia held 52.24% of the market share for paresthesia treatment in 2026. Its leading position reflects higher prevalence and an accessible pathway that often begins with identifying the cause and using first-line medication. Acute symptoms can resolve when the underlying condition is treated, which supports prescription volume in routine care. Chronic paresthesia is forecasted to grow at a 4.22% CAGR from 2027 to 2032. Diabetes, multiple sclerosis, and chemotherapy-related neuropathy can create persistent symptoms that require longer care pathways. The chronic segment therefore has a greater need for coordinated specialty care.Treatment-induced neuropathy of diabetes can also add to chronic case volume when glucose control changes rapidly. The clinical evidence showed that this complication occurred in up to 10.9% of patients when HbA1c declined by at least 2% within 3 months. The risk exceeded 80% when the decline was greater than 4%, which shows why treatment pathways must account for more than disease progression. The FDA’s 2024 guidance for chemotherapy-induced peripheral neuropathy sets clearer development expectations for prevention and treatment products.
Complete Report Scope:
- By Type
- Acute Paresthesia
- Chronic Paresthesia
- By Treatment
- Medications
- Physical Therapy
- Surgery
- Nerve Blocks
- Transcutaneous Electrical Nerve Stimulation
- By Indication and Cause
- Diabetes
- Multiple Sclerosis
- Stroke
- Nerve Injury
- Chemotherapy
- Other Indications and Causes
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 47.62% of the paresthesia treatment market share in 2026. Early adoption of neuromodulation devices, structured reimbursement for interventional neuropathic pain care, and a dense network of specialist pain centers support this position. The FDA approved Medtronic’s Inceptiv closed-loop spinal cord stimulator in April 2024 and Vertex’s Journavx as a non-opioid acute pain therapy in January 2025. Abbott’s January 2026 prone MRI compatibility approval across its neuromodulation portfolio improved imaging access for device users. Eli Lilly is recruiting patients for the decentralized Phase 2 LY4065967 study in diabetic peripheral neuropathic pain, reinforcing the region’s role in testing new pharmacology.Asia-Pacific is forecasted to expand at a 6.24% CAGR through 2032, making it the fastest-growing geography in the paresthesia treatment market. Diabetes incidence, diabetic peripheral neuropathy prevalence, and expanding tertiary care capacity support growth across the region. A pooled analysis found diabetic peripheral neuropathy in 36% of people with diabetes globally and in 39% of developing-country cohorts, creating a large potential patient base in South and Southeast Asia. China approved HSK16149 for adult painful diabetic peripheral neuropathy in May 2024, while Japan’s guidelines include mirogabalin as a first-line option alongside pregabalin. India’s growing tertiary hospital network can absorb more diagnoses, but rural neurologist shortages continue to delay access outside large urban centers.
Europe is moving toward more etiology-specific neuropathic pain care as guidelines refine the role of medicines and noninvasive neuromodulation. A 2025 NeuPSIG review covering 313 double-blind trials and 48,789 adults recommended TCAs, SNRIs, and α2δ ligands as first-line pharmacological options and placed tramadol in third-line treatment. Germany’s October 2025 guidance reinforced individualized management across acute and chronic neuropathy subtypes. In the Middle East and Africa, a 2026 consensus from 12 specialists across 6 GCC countries supported annual diabetic peripheral neuropathy screening and identified restricted access to recommended therapies as a persistent barrier. In South America, a University of São Paulo study completed in May 2025 assessed photobiomodulation and therapeutic ultrasound for people with type 2 diabetes, indicating interest in accessible nonpharmacological treatment options.
List of Companies Covered in this Report:
- Abbott Laboratories
- Abbvie
- Astellas Pharma
- AstraZeneca
- Avanos Medical
- Axogen, Inc.
- Bayer
- Boston Scientific
- Eli Lilly and Company
- GlaxoSmithKline
- Grünenthal GmbH
- Johnson & Johnson
- LivaNova
- Medtronic
- Merck
- Nevro
- Novartis
- Pfizer
- Sanofi
- Teva Pharmaceutical Industries
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- Astellas Pharma Inc.
- AstraZeneca plc
- Avanos Medical, Inc.
- Axogen, Inc.
- Bayer AG
- Boston Scientific Corporation
- Eli Lilly and Company
- GSK PLC
- Grünenthal GmbH
- Johnson & Johnson
- LivaNova PLC
- Medtronic plc
- Merck & Co., Inc.
- Nevro Corp.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.

